Biohit Agrees Distribution Deal for ELISA Test

Tianjin Jingsheng Biological Technology Development Co. Ltd has become a distributor in China for Biohit Oyj’s Calprotectin ELISA test. The test provides quick means of measuring calprotectin in a stool sample and differentiates inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) ; it is also useful for monitoring of treatment in IBD patients.

General Director Zeng Zhao Hong, Tianjin Jingsheng Biological Technology Development Co. Ltd said: “In China there seems to be differences in prevalence of IBD between rural and urban population. The disease is increasing particularly among young people. Fecal calprotectin is an emerging biomarker of gut inflammation. Biohit Calprotectin test differentiates reliably IBD and IBS and reduces significantly the need of colonoscopies.”

CEO Semi Korpela, Biohit Oyj: “We are starting a co-operation with Tianjin Jingsheng Biological Technology Development Co. Ltd in the large Chinese market. We have started the registration in China required to obtain the marketing authorisation for the product.”